Thyquidity Solution
NDC Package 82685-360-02

11-digit billing NDC: 82685036002 · Billing unit: ML · 200 ML per package

Package Information

Thyquidity (levothyroxine sodium) solution is hypothyroidismTHYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) SuppressionTHYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.Limitations of Use:THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with THYQUIDITY may induce hyperthyroidism [seeWarnings and Precautions (5.4)].THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. This formulation utilizes a solution delivery system. Marketed by Oliva Therapeutics, Llc, this product is identified by NDC 82685-360 and is authorized under FDA application NDA214047.

Identification & Billing

NDC Package Code
82685-360-02
Package Description
2 BOTTLE, GLASS in 1 CARTON / 100 mL in 1 BOTTLE, GLASS
Product Code
11-Digit Billing Format
82685036002
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
200 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Thyquidity
Non-Proprietary Name
Levothyroxine Sodium
Substance Name
Levothyroxine Sodium
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
HypothyroidismTHYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) SuppressionTHYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.Limitations of Use:THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with THYQUIDITY may induce hyperthyroidism [seeWarnings and Precautions (5.4)].THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Regulatory & Marketing

Labeler Name
Oliva Therapeutics, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA214047
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-01-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (82685-360). Click a package code to view its specific billing and regulatory data.

1 BOTTLE, GLASS in 1 CARTON / 100 mL in 1 BOTTLE, GLASS

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82685-360-02 identifies a specific commercial package of 2 bottle, glass in 1 carton / 100 ml in 1 bottle, glass of Thyquidity, a human prescription drug labeled by Oliva Therapeutics, Llc. This solution is formulated for oral use and contains levothyroxine sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oliva Therapeutics, Llc on July 01, 2025. The current certification is valid through December 31, 2027.

How is this Oliva Therapeutics, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82685036002. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 200 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82685-360-02
11-Digit CMS (5-4-2)
82685-0360-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.